Combination therapy for bladder cancer patients who cannot take cisplatin
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs, disitamab vedotin and ivonescimab, for people with muscle-invasive bladder cancer who cannot receive standard chemotherapy with cisplatin. The goal is to see if this treatment is safe and effective before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with muscle-invasive bladder cancer (cancer that has grown into the muscle layer of the bladder) that has not spread to other parts of the body.
- You are not able to receive cisplatin chemotherapy due to kidney problems, hearing loss, nerve damage, or poor physical condition.
- Your tumor tests positive for a protein called HER2 (at least 1+ on a scale of 1 to 3).
- You are healthy enough for surgery to remove the bladder (radical cystectomy) and are willing to undergo this surgery as part of the trial.
- You have not had prior immunotherapy, targeted therapy, or biological therapy for bladder cancer.
- Your kidney, liver, and blood counts are within acceptable ranges.
- You agree to use effective contraception during the study and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs (RC48 and toripalimab) given before bladder cancer surgery for patients who cannot take the standard chemotherapy due to kidney problems or other reasons. The goal is to see if this combination can shrink the tumor and improve outcomes.
This study tests a new combination of an antibody-drug conjugate (a targeted therapy) with an immunotherapy drug, plus allergy and vitamin B12 medications, for advanced bladder cancer. It aims to see if this combo is safe and effective for people whose tumors have a certain marker called HER2.
This trial is testing a combination of two drugs (disitamab vedotin and toripalimab) for people with muscle-invasive bladder cancer that has not spread. The goal is to see if this treatment can shrink the tumor before surgery. You may qualify if your tumor has a certain level of a protein called HER2.
This trial tests a new drug combination for advanced bladder or urinary tract cancer that has not been treated before. The study compares a standard chemotherapy plus immunotherapy with and without an extra drug that may reduce side effects.
This trial tests a new combination of two medications—one that targets HER2 on cancer cells and one that boosts your immune system—given directly into the bladder. It is for people with high-risk bladder cancer that hasn't spread into the muscle, and who haven't had BCG therapy or for whom BCG didn't work.
This trial tests a combination of a targeted drug (HDAC inhibitor, given directly into the bladder) and an immunotherapy (Durvalumab, given through a vein) before bladder removal surgery. It's for people with muscle-invasive bladder cancer who cannot take the chemo drug cisplatin.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.